NIVF NIVF
Company Profile ↓Company Overview
NIVF (NIVF) is a publicly traded company listed on with a market capitalization of $49.77K. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 37.1%, reflecting efficient use of shareholder capital.
Net profit has compounded at 178.2% per year over the last five years.
Trades at an undemanding P/E of 0.0.
Carries low leverage with a debt-to-equity ratio of 0.18.
Recent Developments
- Dec 2025 Revenue of $4.73M (-13.0% YoY); net profit $9.88M.
- Trailing 12 Months Year-on-year growth — revenue -13.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -7.4%, profit CAGR 178.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -7.36% |
| 1 Year: | -13.01% |
Compounded Profit Growth
| 5 Years: | 178.23% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -99.85% |
| 6 Months: | -95.96% |
| 3 Months: | -85.83% |
| 1 Month: | -52.62% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)20.14 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 37.1%.
- Profit CAGR of 178.2% over 5 years.
CONS
- Revenue declined at -7.4% CAGR over 5 years.
- Trading 99.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 20 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Sep 2025 | Dec 2025 |
|---|---|---|---|
| Revenue | 1.27M | 1.28M | 1.42M |
| Cost of Revenue | 734.48K | 1.16M | 900.53K |
| Gross Profit | 539.13K | 118.02K | 524.02K |
| Operating Expenses | 1.63M | 2.63M | 5.50M |
| Operating Income | -1.09M | -2.51M | -4.97M |
| EBITDA | -121.58K | 16.80M | -7.27M |
| Interest Expense | 421.11K | 48.09K | 442.84K |
| Pretax Income | -542.68K | 16.75M | -7.72M |
| Tax Provision | -486.71K | 0 | 0 |
| Net Income | -108.24K | 16.82M | -7.67M |
| Diluted EPS | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 5.94M | 5.14M | 5.43M | 4.73M |
| Cost of Revenue | 4.41M | 3.45M | 3.61M | 3.77M |
| Gross Profit | 1.54M | 1.68M | 1.83M | 955.85K |
| Operating Expenses | 1.14M | 1.64M | 2.99M | 11.68M |
| Operating Income | 398.70K | 42.24K | -1.16M | -10.73M |
| EBITDA | 725.69K | 384.31K | 24.11K | 10.84M |
| Interest Expense | 77.76K | 46.18K | 778.66K | 616.42K |
| Pretax Income | 343.99K | 108.42K | -960.81K | 9.73M |
| Tax Provision | 208.14K | 0 | -486.71K | 0 |
| Net Income | 458.67K | 130.19K | -524.64K | 9.88M |
| Diluted EPS | 8,190.48 | 2,324.88 | -4,163.83 | 109.44 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 2.90M | 4.49M | 3.58M | 32.72M |
| Current Assets | - | 2.40M | 2.46M | 3.17M | 7.38M |
| Cash & Equivalents | - | 27.56K | 54.10K | 457.74K | 758.62K |
| Inventory | - | 46.91K | 126.26K | 80.81K | 335.36K |
| Receivables | - | 13.00K | 9.37K | 49.24K | 166.53K |
| Total Liabilities | - | 2.80M | 1.24M | 5.06M | 6.74M |
| Current Liabilities | - | 2.56M | 1.12M | 2.72M | 2.37M |
| Long Term Debt | - | - | - | 2.33M | 4.10M |
| Total Debt | - | 452.04K | 332.55K | 3.03M | 4.86M |
| Total Equity | - | 563.11K | 3.74M | -1.05M | 26.63M |
| Shares Outstanding | - | 56 | 126 | 126 | 80.28K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 1.71M | -1.77M | -8.26M | -10.93M |
| Investing Cash Flow | - | -94.45K | -69.85K | -53.05K | -7.56M |
| Financing Cash Flow | - | -1.63M | 1.88M | 8.68M | 18.99M |
| Capital Expenditure | - | -94.45K | -69.85K | -53.05K | -5.75M |
| Free Cash Flow | - | 1.62M | -1.84M | -8.32M | -16.68M |
| Net Change in Cash | - | -17.33K | 45.51K | 358.67K | 506.93K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 25.9% | 32.7% | 33.6% | 20.2% |
| Operating Margin % | 6.7% | 0.8% | -21.4% | -226.9% |
| Net Margin % | 7.7% | 2.5% | -9.7% | 209.0% |
| ROE % | 81.5% | 3.5% | 50.0% | 37.1% |
| ROCE % | 114.1% | 1.3% | -135.4% | -35.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NIVF
NewGen’s K25.ai Stake Awaits Completion; ~$8.5M Unrealized Gain Expected - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPVkRtaTZIODJnOWdTZmwwaC1vT2I3NHloWVFRQ2JoM3c1SFhUeWNTaDBpZTdJcjlUNUtkbkc2UkE4Y3JjMEl0c1NMYVRQZ0wwb0FKQ0ZBLTVRMm9lRDE1TjBITUNoSGlIUF9Fa1NSR3YwV3FJM3VtWGZNOUxxd3hSRWROSTJoV2hWSWtvZC…
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbmpXeFBiOVZrU1FRSmZrRm9TYTEtQlZwUktmN0Z0MEhqTkNrV2VkSUZfUktpdXVKOEttTnQ2dGRzRG5fbkRVM2kxdlJicGxmWk4wZGVfelgwd1lIdktJSHc5cjI2SWJYVzJHaDJJd1c4aTAtdWZlM0ZPNm9PVE9oaWRTZDBfNFEyQXVtcT…
$NIVF stock is up 21% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPWDVncThLSjkxaWhmY2dMd0RnTjdyNmpQV2JNenBTSVVtSTRvN2s2eE56a19RRlJQM3lHRnZvbncwT2xUT3VYSzBqQ2JTOVN6SmFVUlBncUJ5X2U5STFUbndfd2pqR2MzdmVUZm5NNWFIRHJxaWtycFIyU3V1YmpNc3NwUDkyM3ZSZk5ZSW…
NIVF Stock Snaps Higher As Traders Focus On Volatility And Value - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPdDRGSFBCcnJpcFE3cDhZTjNsSHNUTWI4SVJReGRpYUQ3cXBiQzFvUlRtWFpJeDBVdm14WDFOZ3RmY1dESFZ1d1dfOFNDRkNMY2xRWXpDU2QyeEVyb2RDaW9qV2hVOUMyZjlsMFczWTBGdFdvcmJTZU1fekZVajRkSW1n?oc=5" target=…
NewGenIvf Group Limited Revenue Breakdown – NASDAQ:NIVF - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBYVndEZlM1VFcyMEgzNWVjWlluOGZoNEYzVENHVU5faTd1a3RoSXU4MXM3dHJuRk13cXEyei1JMV9vNzZpZlczM1JDbEZuaUg2ZVVLTjRsWHdEZ2MtQmpYejd6WmtyaW10azhhZ05NN3FMQUdIM0g4?oc=5" target="_blank">NewGenI…
NIVF Stock Slides After Volatile Spike Draws Trader Focus - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQME16Z0RQTWgxU0N2NDJaTTNVc0JPMFVwalhETFR3aGJobmplYWxiY2paSTZma0tnNnhoVlZrMTBteGJHUkRkZDAyMm9qRy1zN01Ic0RxdzBzckhLV3FBdW1EY0JNM1k0c3BZdC1VWEhPVEJubTZ2NnVxWjE2dmJJTzVBRQ?oc=5" targe…
NIVF — Frequently Asked Questions
What is the current share price of NIVF?
As of 2026-08-05 17:25 PDT, NIVF trades at $0.62 on NASDAQ/NYSE. Its 52-week range is $0.61 to $424.80.
What is the market capitalisation of NIVF?
NIVF has a market capitalisation of $49.77K on NASDAQ/NYSE.
What is the P/E ratio of NIVF?
NIVF trades at a trailing price-to-earnings (P/E) ratio of 0.01.
What is the return on equity (ROE) of NIVF?
NIVF has a return on equity (ROE) of 37.10%. Its return on capital employed (ROCE) is -35.34%.
Is NIVF a good stock to buy?
This page provides a data-driven analysis of NIVF, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.